F Marc LaForce

Summary

Affiliation: Program for Appropriate Technology in Health
Country: USA

Publications

  1. ncbi request reprint The Meningitis Vaccine Project
    F Marc LaForce
    The Meningitis Vaccine Project, PATH, 13 Chemin du Levant, 01210 Ferney Voltaire, France
    Vaccine 25:A97-100. 2007
  2. doi request reprint Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution
    F Marc LaForce
    PATH, 13 Chemin du Levant, Ferney Voltaire 01210, France
    Vaccine 27:B13-9. 2009
  3. ncbi request reprint Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries
    Luis Jodar
    WHO, Geneva, Switzerland
    Lancet 361:1902-4. 2003
  4. ncbi request reprint Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project
    Montse Soriano-Gabarro
    Meningitis and Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Health Popul Nutr 22:275-85. 2004
  5. ncbi request reprint The promise of conjugate vaccines for Africa
    Marie Paule Kieny
    Initiative for Vaccine Research, World Health Organization, Av Appia 20, 1211 Geneva 27, Switzerland
    Vaccine 25:A108-10. 2007
  6. ncbi request reprint From genomics to surveillance, prevention and control: new challenges for the African meningitis belt
    Jean Michel Alonso
    Institut Pasteur, National Reference Centre for Meningococci, Neisseiria Unit, Department of Molecular Medicine, Paris, France
    Vaccine 24:4279-84. 2006
  7. ncbi request reprint Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults
    Nilima Kshirsagar
    Seth G S Medical College and KEM Hospital Parel, Mumbai, India
    Vaccine 25:A101-7. 2007

Collaborators

Detail Information

Publications7

  1. ncbi request reprint The Meningitis Vaccine Project
    F Marc LaForce
    The Meningitis Vaccine Project, PATH, 13 Chemin du Levant, 01210 Ferney Voltaire, France
    Vaccine 25:A97-100. 2007
    ..The MVP model is a clear example of the usefulness of a "push mechanism" to finance the development of a needed vaccine for the developing world...
  2. doi request reprint Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution
    F Marc LaForce
    PATH, 13 Chemin du Levant, Ferney Voltaire 01210, France
    Vaccine 27:B13-9. 2009
    ..Widespread use of such a vaccine is likely to generate herd immunity and to put an end to Group A meningococcal epidemics...
  3. ncbi request reprint Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries
    Luis Jodar
    WHO, Geneva, Switzerland
    Lancet 361:1902-4. 2003
  4. ncbi request reprint Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project
    Montse Soriano-Gabarro
    Meningitis and Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Health Popul Nutr 22:275-85. 2004
    ..Other studies will include evaluations of safety, vaccine coverage, impact on carriage and herd immunity, and prevention-effectiveness studies...
  5. ncbi request reprint The promise of conjugate vaccines for Africa
    Marie Paule Kieny
    Initiative for Vaccine Research, World Health Organization, Av Appia 20, 1211 Geneva 27, Switzerland
    Vaccine 25:A108-10. 2007
    ..A review of the evidence in order to analyse how to optimize immunization schedules for conjugate vaccines is warranted...
  6. ncbi request reprint From genomics to surveillance, prevention and control: new challenges for the African meningitis belt
    Jean Michel Alonso
    Institut Pasteur, National Reference Centre for Meningococci, Neisseiria Unit, Department of Molecular Medicine, Paris, France
    Vaccine 24:4279-84. 2006
  7. ncbi request reprint Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults
    Nilima Kshirsagar
    Seth G S Medical College and KEM Hospital Parel, Mumbai, India
    Vaccine 25:A101-7. 2007
    ..This opens the prospective for further development and licensure of this vaccine to eliminate epidemic meningitis in sub-Saharan Africa...